Literature DB >> 32427318

Role of low-level quinolone resistance in generating tolerance in Escherichia coli under therapeutic concentrations of ciprofloxacin.

M Ortiz-Padilla1,2,3,4, S Diaz-Diaz1,2,3,4, J Machuca1,2,3,4, A Tejada-Gonzalez2, E Recacha1,3,4, F Docobo-Pérez2,3,4, A Pascual1,2,3,4, J M Rodríguez-Martínez2,3,4.   

Abstract

BACKGROUND: Tolerance (including persistence) and resistance result in increased survival under antibiotic pressure.
OBJECTIVES: We evaluated the interplay between resistance and tolerance to ciprofloxacin under therapeutic and killing conditions to determine the contribution of low-level quinolone resistance (LLQR) mechanisms to tolerance. We also determined how the interaction between resistance (LLQR phenotypes) and tolerance was modified under SOS response suppression.
METHODS: Twelve isogenic Escherichia coli strains harbouring quinolone resistance mechanisms combined with SOS response deficiency and six clinical E. coli isolates (LLQR or non-LLQR) were evaluated. Survival (tolerance or persistence) assays were used to measure surviving bacteria after a short period (up to 4 h) of bactericidal antibiotic treatment under therapeutic and killing concentrations of ciprofloxacin [1 mg/L, EUCAST/CLSI breakpoint for resistance; and 2.5 mg/L, peak serum concentration (Cmax) of this drug].
RESULTS: QRDR substitutions (S83L in GyrA alone or combined with S80R in ParC) significantly increased the fraction of tolerant bacteria (2-4 log10 cfu/mL) after exposure to ciprofloxacin at clinically relevant concentrations. The impact on tolerant bacteria due to SOS response suppression (including persistence mediated by the tisB gene) was reversed by LLQR mechanisms at therapeutic concentrations. Furthermore, no reduction in the fraction of tolerant bacteria due to SOS response suppression was observed when S83L in GyrA plus S80R in ParC were combined.
CONCLUSIONS: Tolerance and quinolone resistance mutations interact synergistically, giving LLQR mechanisms an additional role in allowing bacterial survival and evasion of therapeutic antimicrobial conditions by a combination of the two strategies. At clinically relevant concentrations, LLQR mechanisms reverse further impact of SOS response suppression in reducing bacterial tolerance.
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32427318     DOI: 10.1093/jac/dkaa151

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

1.  Stepwise selection of mutation conferring fluroquinolone resistance: multisite MDR-TB cohort study.

Authors:  Jingtao Gao; Jian Du; Wei Shu; Yuhong Liu; Yufeng Wang; Zhongtan Xue; Liang Li; Yu Pang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-02-18       Impact factor: 3.267

2.  Repeated Exposure of Escherichia coli to High Ciprofloxacin Concentrations Selects gyrB Mutants That Show Fluoroquinolone-Specific Hyperpersistence.

Authors:  Aurore Perault; Catherine Turlan; Nathalie Eynard; Quentin Vallé; Alain Bousquet-Mélou; Etienne Giraud
Journal:  Front Microbiol       Date:  2022-05-30       Impact factor: 6.064

3.  Ciprofloxacin Pharmacokinetics/Pharmacodynamics against Susceptible and Low-Level Resistant Escherichia coli Isolates in an Experimental Ascending Urinary Tract Infection Model in Mice.

Authors:  Lotte Jakobsen; Carina Vingsbro Lundberg; Niels Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

4.  The Persister Character of Clinical Isolates of Staphylococcus aureus Contributes to Faster Evolution to Resistance and Higher Survival in THP-1 Monocytes: A Study With Moxifloxacin.

Authors:  Tiep K Nguyen; Frédéric Peyrusson; Magali Dodémont; Nhung H Pham; Hoang A Nguyen; Paul M Tulkens; Françoise Van Bambeke
Journal:  Front Microbiol       Date:  2020-11-23       Impact factor: 5.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.